- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Biotech Options Buzz: UTHR, NMRA, EWTX | 11 | Schaeffer's Research | ||
| 14.08. | Neumora Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 14.08. | Neumora Therapeutics GAAP EPS of -$0.23 beats by $0.01 | 5 | Seeking Alpha | ||
| 14.08. | Neumora Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | 596 | GlobeNewswire (Europe) | Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzheimer's disease (AD) agitation... ► Artikel lesen | |
| 27.07. | Neumora reports favorable toxicology results for obesity drug | 14 | Investing.com | ||
| NEUMORA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.07. | Neumora meldet positive Toxikologie-Daten für Adipositas-Wirkstoff | 3 | Investing.com Deutsch | ||
| 27.07. | Neumora Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.07. | Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026 | 303 | GlobeNewswire (Europe) | WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target... ► Artikel lesen | |
| 22.06. | Neumora stock price target lowered to $4 by Mizuho on trial failure | 8 | Investing.com | ||
| 17.06. | Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant's Upcoming Depression Data | 12 | Insider Monkey | ||
| 16.06. | Neumora depression drug fails; EnGene to cut 50% of staff | 4 | BioPharma Dive | ||
| 16.06. | Needham cuts Neumora stock price target on navacaprant discontinuation | 10 | Investing.com | ||
| 16.06. | Neumora stock price target cut to $7 on failed trial, H.C. Wainwright maintains buy | 10 | Investing.com | ||
| 15.06. | Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail | 3 | Benzinga.com | ||
| 15.06. | Neumora plummets as phase 3 navacaprant data misses key goal | 3 | Seeking Alpha | ||
| 15.06. | Neumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studies | 5 | FierceBiotech | ||
| 15.06. | Neumora stoppt Depressionsmedikament nach Studienfehlschlag und kündigt Stellenabbau an | 6 | Investing.com Deutsch | ||
| 15.06. | Neumora Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.06. | Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update | 350 | GlobeNewswire (Europe) | Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer's disease... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,80 | +0,18 % | Biontech-Großaktionär rechnet mit baldiger Vorstands-Neubesetzung | Mainz - Einer der Großaktionäre und Mitgründer von Biontech, Thomas Strüngmann, rechnet mit einer baldigen Neubesetzung im Vorstand des Mainzer Biotechunternehmens."Die Berufung eines neuen Medizinvorstands... ► Artikel lesen | |
| MODERNA | 134,16 | +0,12 % | Moderna-Aktie bei 144 US$: Nächstes Hoch in Sicht? | Die Moderna-Aktie konnte gestern um +5,38% zulegen, nachdem der Kurs zuvor rund -34% korrigiert hatte. Damit zeigt sich nach dem deutlichen Rücksetzer eine erste Gegenbewegung. Nun stellt sich die entscheidende... ► Artikel lesen | |
| AMGEN | 335,15 | -0,16 % | Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the FDA approved an update to the IMDELLTRA Prescribing Information that substantially reduces the recommended monitoring time for the first... ► Artikel lesen | |
| NOVAVAX | 8,670 | -1,37 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| BIOGEN | 189,04 | +0,74 % | Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen | |
| ILLUMINA | 210,00 | +0,70 % | Biotech Stocks At 52-Week Highs - BlossomHill Therapeutics +18% On Positive Trial Data, Adaptive Biotechnologies, Illumina, CeriBell, Neogen | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 16, 2026, driven by positive results from clinical trials or an upcoming conference participation.BlossomHill... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,155 | -0,17 % | CRISPR Therapeutics auf Morgan Stanley Konferenz: Pipeline-Erweiterung und kommerzielle Fortschritte | ||
| INOVIO PHARMACEUTICALS | 1,077 | +9,40 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,100 | -0,59 % | Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. | ||
| INFLARX | 1,842 | +0,99 % | Klinische Daten geben InflaRx NV neuen Schub: Der Weg über 2 EUR | ||
| INTELLIA THERAPEUTICS | 10,360 | -2,08 % | Cathie Wood's ARK sells Twist Bioscience stock, buys more Intellia | ||
| TEMPUS AI | 67,70 | -0,09 % | Tempus AI stock is soaring: does it have more upside to go? | ||
| EDITAS MEDICINE | 2,370 | +0,85 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,490 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,385 | -2,78 % | Bis zu 5,4 Millionen US-Dollar pro Patient: Warum Medtronic, Globus Medical und NurExone an derselben Verletzung ansetzen |
NEUMORA THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,725 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUMORA THERAPEUTICS INC finden Sie auf Wallstreet Online.